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1015-9584/Copyright ª 2015, Asian SuSummary Background: Central lymph node dissection (CLND) in patients with papillary thy-
roid microcarcinoma (PTMC) is still controversial. The aim of this study was to examine the risk
factors and the incidence of central lymph node metastases (CLNMs) in patients with PTMC
who underwent thyroidectomy and CLND.
Patients and methods: Between 2002 and 2013, 613 patients were enrolled who underwent
thyroidectomy with routine CLND for PTMC at the Korea University Medical Center, Ansan Hos-
pital and risk factors and the incidence of CLNM were analyzed. In addition, we also evaluated
the complications after thyroidectomy with CLND.
Results: Out of 613 patients, 239 (39.0%) were found to have CLNM. Male sex (pZ 0.012), tu-
mor size  0.5 cm (pZ 0.001), capsular invasion or extrathyroidal extension (pZ 0.029), and
multifocality (pZ 0.004) were independent risk factors for CLNM. Among the 69 patients who
had PTMC without these risk factors, CLNM was identified in 12 (17.4%). In this study group, two
(0.3%) had permanent recurrent laryngeal nerve injury, two (0.3%) had persistent hypocalce-
mia, and two (0.3%) developed postoperative hemorrhage.
Conclusion: CLNM in PTMC is highly prevalent in male sex, tumor size  0.5 cm, extrathyroidal
extension, and multifocality. Even in PTMC patients without these risk factors, the incidence of
CLNM is rather higher than expected, and the complication rate of thyroidectomy with CLND is
acceptable. Thus, CLND should be considered in all patients with PTMC.
Copyright ª 2015, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.s supported by Korea University Grant (K1032401).
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198 Y.W. Chang et al.1. IntroductionTable 1 Clinicopathological characteristics (n Z 613).
Characteristic n (%)
Age (y) 46.2 (10.5)
Sex
Female 558 (91.0)
Male 55 (9.0)
Tumor size (cm)
Mean 0.8 (0.4)
< 0.5 126 (20.6)
 0.5 487 (79.4)
Extrathyroidal extension
No 264 (43.1)
Yes 349 (56.9)
Multifocality
No 461 (75.2)
Yes 152 (24.8)
Central lymph node metastasis
No 374 (61.0)
Yes 239 (39.0)
Lymphovascular invasion
No 597 (97.4)
Yes 16 (2.6)
Thyroiditis
No 320 (52.2)
Yes 293 (47.8)Papillary thyroid microcarcinoma (PTMC) is defined as a
papillary thyroid carcinoma (PTC) measuring  1 cm in
maximal diameter, and the overall 10-year survival rate
associated with this malignancy is > 90%.1,2 Because of the
overall excellent prognosis of PTMC, many current guide-
lines and recommendations regarding the optimal treat-
ment strategy for PTMC remain controversial.3,4
Many arguments about PTMC treatments have focused on
routine central lymph node dissection (CLND), because
despite the excellent prognosis, central lymph node me-
tastases (CLNMs) are common in patients with PTC. Several
studies have reported that CLNM are associated with a
significantly increased probability of locoregional disease
recurrence, and routine CLND for PTC patientsmay decrease
recurrence and improve disease-specific survival.5e9
However, Ito et al10 have insisted that prophylactic CLND
may result in postoperative complications and provides no
overall survival benefit. Moreover, the 2009 guidelines for
the management of thyroid nodules and differentiated
thyroid cancer issued by the American Thyroid Association
Guidelines Taskforce state the following: “Prophylactic
central-compartment neck dissection (ipsilateral or bilat-
eral) may be performed in patients with papillary thyroid
carcinoma with clinically uninvolved central neck lymph
nodes, especially for advanced primary tumors.”11
To investigate the efficacy and indication of CLND for
PTMC patients, we examined the overall incidence and risk
factors of CLNM in our cases. In addition, we also analyzed
the complications and incidence of CLNM in PTMC patients
without risk factors.
2. Patients and methods
A total of 613 patients who underwent thyroidectomy with
routine CLND for PTMC at the Korea University Medical
Center, Ansan Hospital, between January 2002 and
December 2013 were enrolled in this study. Based on a
review of our computerized database, the following data
were collected: demographic information and pathological
parameters, such as tumor size, extra thyroidal extension,
multifocality, cervical lymph node metastasis, lymphovas-
cular invasion, and thyroiditis. This study was approved by
the Institutional Review Board of Korea University Medical
Center, Ansan Hospital.
All 613 patients underwent hemithyroidectomy or total
thyroidectomy with routine CLND. Hemithyroidectomy with
ipsilateral CLND was performed in 205 patients because
they had single lesions that were limited to the thyroid and
clinically negative radiologic findings in the central lymph
node, and four underwent subsequent completion thyroid-
ectomy. Among the remaining 408 patients, 310 patients
with clinically node negative findings underwent total thy-
roidectomy with ipsilateral CLND, and bilateral CLND was
performed in 98 patients with clinically suspicious node
metastasis or bilateral lesions. CLND was performed supe-
riorly to the hyoid bone, laterally to the carotid sheath,
inferiorly to the manubrium, and dorsally to the preverte-
bral fascia. The parathyroid glands were carefully pre-
served in situ, and the devascularized parathyroid glandswere autotransplanted into the sternocleidomastoid
muscle.
The incidence rates of recurrent laryngeal nerve injury,
hypocalcemia, and postoperative hemorrhage were evalu-
ated. Temporary recurrent laryngeal nerve injury was
based on the surgeon’s assessment and the patient’s
symptoms during the immediate postoperative day. Recur-
rent laryngeal nerve injury was considered permanent
when paralysis of the vocal cords persisted > 6 months
after the surgery. Transient hypocalcemia was defined as an
ionized calcium level < 1.0 mg/dL postoperatively but
recovered until 6 months, and permanent hypocalcemia
was defined as persistent hypocalcemia requiring calcium
carbonate and calcitriol supplementation > 6 months after
the surgery. Performing an emergency evacuation of a he-
matoma after thyroidectomy was considered postoperative
hemorrhage.
Categorical variables were compared using the Chi-
square test or Fisher’s exact test to analyze the signifi-
cance of differences. Logistic regression was used for
multivariate analysis. Differences were considered statis-
tically significant with p  0.05 using a two-tailed test. All
statistical analyses were performed using SPSS Statistics
version 20.0.0 for Macintosh (IBM, Armonk, NY, USA).
3. Results
3.1. Patient characteristics and pathology
The patient clinicopathological characteristics are sum-
marized in Table 1. The study population included 558
women (91.0%) and 55 men (9.0%) with a mean age of
Table 3 Incidence of central lymph node metastasis in
patients with PTMC.
Central lymph node
metastasis, n (%)
Total
Negative Positive
Total 374 (61.0) 239 (39.0) 613 (100)
Without RFs 57 (82.6) 12 (17.4) 69 (100)
PTMC Z papillary thyroid microcarcinoma; RF Z risk factor.
Central lymph node dissection for papillary thyroid microcarcinoma 19946.2  10.5 years. The mean size of PTMCs was
0.8  0.4 cm; 126 (20.6%) patients had PTMCs < 0.5 cm and
487 (79.4%) patients had PTMCs  0.5 cm in size. Of these
patients, 264 (43.1%) patients had PTMC confined to the
thyroid, and 349 (56.9%) patients had PTMC with extra-
thyroidal extension. Multifocality was observed in 152
(24.8%) patients, lymphovascular invasion was found in 16
(2.6%) patients, and thyroiditis was found in 293 (47.8%)
patients. CLNMs were identified in 239 (39.0%) patients.
3.2. Risk factors associated with CLNMs
Male sex [odds ratio (OR), 2.17; 95% confidence interval
(CI), 1.24e3.80; pZ 0.006], tumor size  0.5 cm (OR, 2.83;
95% CI, 1.78e4.49; p < 0.001), extrathyroidal extension
(OR, 1.93; 95% CI, 1.38e2.70; p < 0.001), and multifocality
(OR, 2.11; 95% CI, 1.46e3.06; p < 0.001) were significantly
associated with CLNM. Age, lymphovascular invasion, and
thyroiditis were not significantly associated with CLNM.
After all variables with p < 0.5 in the univariate analysis
were input into the logistic regression model, male sex (OR,
2.10; 95% CI, 1.18e3.75; p Z 0.012), tumor size  0.5 cm
(OR, 2.29; 95% CI, 1.42e3.69; p Z 0.001), extrathyroidal
extension (OR, 1.49; 95% CI, 1.04e2.13; p Z 0.029), and
multifocality (OR, 1.76; 95% CI, 1.19e2.59; p Z 0.004)
remained as independent risk factors of CLNM (Table 2).
3.3. CLNM incidence and postoperative
complications
Overall, 39% of PTMC patients (239 of 613) had pathologi-
cally metastatic lymph nodes in the central compartment.Table 2 Risk factors associated with cervical lymph node meta
Risk factor Cervical LN metastasis
Negative Positive OR
Age (y) 0.9
< 45 167 109
 45 207 130
Sex 2.1
Female 350 208
Male 24 31
Tumor size (cm) 2.8
< 0.5 99 27
 0.5 275 212
LV invasion 2.6
No 368 229
Yes 6 10
Extrathyroidal extension 1.9
No 184 80
Yes 190 159
Multifocality 2.1
No 302 159
Yes 72 80
Thyroiditis 1.0
No 196 124
Yes 178 115
CI Z confidence interval; LN Z lymph node; LV Z lymphovascular; OAmong the 69 PTMC patients without all four risk factors
shown in Table 2, 17.4% (12 of 69) had CLNM (Table 3).
Thirteen (2.1%) patients experienced temporary recur-
rent laryngeal nerve palsy, and two (0.3%) patients had
permanent recurrent laryngeal nerve palsy. Transient hy-
pocalcemia occurred in 74 (12.1%) patients, and hypocal-
cemia persisting > 6 months after the operation occurred in
two (0.3%) patients. Emergency operations for post-
operative hemorrhage were performed in two (0.3%) pa-
tients (Table 4).4. Discussion
Male sex, tumor size  0.5 cm, extrathyroidal extension,
and multifocality were associated with a significantly
increased risk of CLNM in our study. In general, smaller
lesion size and female sex are considered good prognostic
factors of PTC.12e14 Lim et al15 and Zhang et al16 have also
demonstrated that larger tumor size (> 0.7 cm, > 0.6 cm)
was associated with CLNM. Male sex and tumor size stasis.
Univariate analysis Multivariate analysis
(95% CI) p OR (95% CI) p
6 (0.69e1.33) 0.817
7 (1.24e3.80) 0.006 2.10 (1.18e3.75) 0.012
3 (1.78e4.49) < 0.001 2.29 (1.42e3.69) 0.001
8 (0.96e7.47) 0.051
3 (1.38e2.70) < 0.001 1.49 (1.04e2.13) 0.029
1 (1.46e3.06) < 0.001 1.76 (1.19e2.59) 0.004
2 (0.74e1.41) 0.899
R Z odds ratio.
Table 4 Postoperative complications.
Complication Number of patients (%)
Recurrent laryngeal nerve palsy
Temporary 13 (2.1)
Permanent 2 (0.3)
Hypocalcemia
Transient 74 (12.1)
Permanent 2 (0.3)
Postoperative hemorrhage 2 (0.3)
200 Y.W. Chang et al.0.5 cm were independent risk factors of CLNM in this study,
and these results are compatible with those of other re-
ports in PTMC patients.15,16 In the present study, extra-
thyroidal extension and multifocality also correlated with
CLNM. Similar studies in PTMC have shown that extra-
thyroidal extension is associated with CLNM (p < 0.001) and
recurrence (p Z 0.037), and multifocality has also been
shown to be an independent risk factor of CLNM.17e20 Ac-
cording to Mazeh et al,21 multifocality may develop by
intraglandular spread of the primary tumor, and this may be
related to CLNM.
CLNMs are relatively common in PTMC patients. Several
studies have demonstrated that CLNMs are observed in
about 31e64.1% of patients with PTMC.15,22,23 In this study,
the incidence of CLNMs in patients with PTMC was 39.0%. To
analyze the feasibility of prophylactic CLND for PTMC pa-
tients with no clinical risk factors, we also evaluated the
incidence of CLNM in PTMC patients without any of these
four risk factors. Even after the elimination of risk factors,
the incidence of CLNM in these patients was 17.4%. Hence,
the prediction of CLNM using only these risk factors should
be considered unsafe.
Appetecchia et al24 do not believe that CLND is neces-
sary, because the reported mortality rates of PTMC range
from 0% to 1%, and CLND provides no survival benefit
despite the high incidence of CLNM. In addition, Wada
et al23 have reported that CLND may increase the frequency
of perioperative complications, such as recurrent laryngeal
nerve injury, hypocalcemia, or immediate postoperative
bleeding.23
However, Chow et al25 showed that the risk of locore-
gional recurrence (OR, 4.2; 95% CI, 1.3e13.6) and cervical
lymph node recurrence (OR, 6.2; 95% CI, 1.6e24.4) signifi-
cantly increased in PTMC patients with CLNM, and the
presence of cervical lymph node metastasis also increased
the incidence rate of distant metastasis (OR, 11.2; 95% CI,
1.3e100.7).25 Simon et al26 have also suggested that lymph
node metastases are significantly associated with a higher
risk of recurrence. Vini et al27 recommended routine CLND
for patients aged  70 years. They indicated that radioac-
tive iodine ablation may not be effective because the ca-
pacity of thyroid tumor cells for radioactive iodine uptake
is reduced in elderly people.27 Furthermore, Levin et al28
have demonstrated that the operations for recurred
lymph nodes in PTC increased the risk of postoperative
complications. In addition, CLND is helpful to assess the
accurate staging of lymph node.28
Currently, the diagnostic performance of ultrasonogra-
phy (US) for determining the presence of CLNM in PTMCpatients is not completely reliable. The sensitivity of US in
predicting CLNM for PTMC patients has been reported to
range from 21.6% to 38.0%.29e31 Kim et al31 also showed
that the false negative rate of US at the central neck level
was 30% (32/107). As described above, although US findings
can indicate clinically negative nodes in the central neck
compartment, this does not guarantee pathologically
negative nodes.
The risk of postoperative complications is one concern
about performing CLND in PTMC patients. According to a
study by Henry et al32 that compared the complications
after thyroidectomy only with thyroidectomy and CLND,
CLND does not increase the incidence of recurrent laryn-
geal nerve injury. Gemsenja¨ger et al33 described that 1e2%
of patients who underwent total thyroidectomy only
experienced permanent hypocalcemia or permanent
recurrent laryngeal nerve injury, and the rate of compli-
cations was not increased with the addition of CLND. In this
study, 0.3% of patients had permanent recurrent laryngeal
nerve injury, and another 0.3% of patients experienced
permanent hypocalcemia. These results are compatible
with those of another study.34 The postoperative compli-
cations appear to be related to surgical experiences, and
experts can perform CLND safely.
In conclusion, the incidence of CLNM in PTMC patients
(even with no risk factors) was not infrequent, whereas the
rate of postoperative complications after CLND was
acceptably low. Thus, CLND should be considered for even
PTMC patients.References
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